FVC
risdiplam
FVC was assessed in patients aged 6–25 years at screening. In patients who received risdiplam for 24 months, the mean change from baseline in the best percentage-predicted FVC (95% CI) was – 7.8% (– 11.6 to – 3.9%) after 24 months of risdiplam treatment (Table 